Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of induced pluripotent stem cells. Then in 2007, a series of follow-up experiments done at Kyoto University successfully transformed human adult cells into iPSCs.
Interestingly, the number of iPSC research products sold worldwide has been growing at an annual rate of 14.7% over the past five years.
In addition, 22.1% of all stem cell researchers now report having used iPSCs within a research project. It is clear that iPSCs are a vital research trend within the scientific community.
To capture these trends and more, BioInformant surveyed 274 researchers (131 U.S. / 143 International) that identify as having induced pluripotent stem cells as their core focus.
The survey reveals needs, technical preferences, and key factors influencing buying decisions among iPSC researchers. It can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.
Can you imagine getting into the mind of iPSC researchers? If so, I’m surprised and impressed.
If not, click here to view the “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report,” which contains BioInformant survey of iPSC researchers – and so much more.
BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.